Veterinary Vaccines Market

KEY INSIGHTS

External partnerships in veterinary research driving veterinary vaccine development

External partnerships and strategic collaborations between companies and the academia are expected to drive R&D and the revenue growth of the veterinary vaccine market. For example, veterinary vaccine manufacturer Zoetis revealed that through two collaborative research projects funded by the 6th and 7th EU Framework Programs, Suvaxyn CSF Marker, a potent new live marker in veterinary vaccines for Classic Swine Fever (CSF), was developed, validated and finally approved by EMA in February 2015. Manufacturers of veterinary vaccines stress upon the importance of regular constructive communication for successful external R&D collaborations for the development of veterinary vaccines.

Declining popularity of anti-microbial drugs fuelling the demand for veterinary vaccines

The demand for veterinary vaccines is increasing as antimicrobial usage among farm as well as companion animals has reducing over the past five years. Fears of avian influenza and zoonosis, coupled with government initiatives to restrict Antimicrobial Drug Resistance (AMR) in animals and human beings, are fuelling the demand for veterinary vaccines. These veterinary vaccines reduce reliance on anthelmintic and antimicrobial drugs for treating infections. Manufacturers of veterinary vaccines are adopting advanced technology to develop better veterinary vaccines, such as live attenuated and recombinant, to curb zoonotic diseases.

Downstream consolidation weakens the bargaining power of veterinary vaccine manufacturers

Veterinary vaccine manufacturers are largely dependent upon governments of individual countries and respective veterinary vaccine departments for large-volume sales. Veterinary vaccine manufacturers resort to tender-based and direct sales routes for distribution to large farms in developed countries. Veterinary vaccines for livestock are purchased in bulk, while companion animal veterinary vaccines are purchased on a retail basis, primarily for welfare purposes. A consolidation in the downstream, i.e. between distributors, puts pressure on the already crunched margins in the veterinary vaccines market. This restraint is primarily noted among animal farms located in developed countries dealing with cattle and hog population. The development of cold chain and storage systems is another factor hampering the distribution of veterinary vaccines in less-developed markets.

Expansion in the MEA market likely to boost the revenues of veterinary vaccine manufacturers

Veterinary vaccine manufacturers are likely to benefit from expanding their presence in the MEA region. The large cattle population in the MEA and the growing demand for poultry & milk products in the Middle East is driving the demand for feed additives, veterinary vaccines and drugs. Steady government support and increased international funding for developing cold chains for the transportation of veterinary vaccines is likely to boost the revenue. Increase in the number of initiatives undertaken by various governments in Africa to promote aquaculture is projected to fuel the demand for adequate veterinary vaccines.

Increased demand for lean meat fuelling the demand for veterinary vaccines in the poultry segment

Globally, there is an increase in the demand for lean meat in the food basket as against red meat. This is fuelling the demand for veterinary vaccines in the poultry segment. In this regard, Erick Lelouche, President of Boehringer Ingelheim Animal Health France noted that “As poultry consumption continues to rise around the world, there is an increasing demand for avian veterinary vaccines. This means that our LPA production site in Saint-Priest was going to reach a saturation point by 2020. We had to do some forward planning and find additional production capacity.” This indicates additional expansion for the manufacturing of avian veterinary vaccines by the leading manufacturers of veterinary vaccines around the world. 

Note: For a detailed analysis of all the key market factors, request a sample.

Competitive Landscape

The FMI report titled “Veterinary Vaccines Market” provides detailed information about the growth parameters of the key players of the veterinary vaccines market. It includes a detailed competitive assessment of the veterinary vaccines market. The market study provides comprehensive data on different stakeholders in the veterinary vaccines market, which include Zoetis, Elanco, Merck & Co. Inc., Boehringer Ingelheim GmbH )(BIVI), Bayer Pharma AG, Ceva, Virbac, Diamond Animal Healthcare (Heska) and Indian Immunological Ltd. The veterinary vaccines report provides readers all-encompassing data on the revenue shares of veterinary manufacturers, winning strategies and latest information on mergers and acquisitions in the veterinary vaccines market.

Considering the rapidly-growing veterinary vaccines market, expansion in emerging economies is taking centre stage. Some of the latest M&A big ticket deals in the veterinary vaccines market have been elaborated in this report. For instance, Elanco completed the acquisition of Boehringer Ingelheim Vetmedica, Inc.’s (BIVI) U.S. feline, canine and rabies vaccines portfolio in January 2017. Elanco also acquired Lohaman Animal Health, which has a significant presence in the poultry vaccine segment. In addition, technological advancements are fuelling the entry of novel veterinary vaccines. In May 2016, Bayer signed an agreement with BioNTech AG for exclusively developing novel mRNA veterinary vaccines and therapeutics for animal health applications.

Note: For full coverage of the competitive landscape, get in touch with our experts.

Definition

Veterinary vaccines are a cost-effective prophylactic method to prevent veterinary diseases. Veterinary vaccines enhance the efficiency of food production and reduce or prevent the transmission of zoonotic & foodborne infections to people. The veterinary vaccines market report encompasses attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines and recombinant vaccines. Attenuated live vaccines and inactive vaccines are the most widely manufactured veterinary vaccines. Attenuated live veterinary vaccines are derived from disease-causing pathogens, such as virus or bacteria, which have been weakened under laboratory conditions. Inactivated veterinary vaccines are made from microorganisms, such as viruses, bacteria and others, which have been killed through physical or chemical processes.

About the Report

The market study on the veterinary vaccines market was recently published by FMI. It provides comprehensive information about the most important veterinary vaccines market dynamics that are expected to prove instrumental during 2016-2026. Companies in the veterinary vaccines market can find the most accurate quantitative and qualitative information about the growth parameters of other veterinary vaccines manufacturers, which can help them develop data-driven business strategies in the near future.

Segmentation

The FMI report on the veterinary vaccines market provides salient information about market players. The veterinary vaccines market is segmented by geographical region, product type, disease application, animal type, disease application and distribution channels to analyse the segment-wise growth of the veterinary vaccines market. Based on the geographical region, the veterinary vaccines market is segmented into seven regions: North America, Latin America, Western Europe, Eastern Europe, Japan, Asia Pacific Excluding Japan (APEJ) and the Middle East & Africa (MEA). The veterinary vaccines market is segmented into product types, viz. attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines and recombinant vaccines. Depending upon the disease type, the veterinary vaccines market is segmented into anaplasmosis, canine parvovirus, foot & mouth disease, Newcastle disease, distemper disease, influenza, Porcine Reproductive & Respiratory Syndrome (PRRS) and others. By animal type, the market is segmented into companion animals, livestock animals and equine. By distribution channel, the veterinary vaccines market is segmented into veterinary clinics, veterinary hospitals, veterinary research institutes and retail pharmacies.

Additional Questions Answered

Readers can find detailed information about the important positive and negative factors that are expected to affect the veterinary vaccines market during the forecast period. In addition, the veterinary vaccines market report also contains valuable information that can provide biopharmaceutical contract manufacturers answers to critical questions, such as:

• Which product types account for the maximum demand in the veterinary vaccines market? Why are the sales of veterinary vaccines the highest in North America?

• Which regulations in various regions are influencing the strategies of players in the veterinary vaccines market?

• What are the current technology trends adopted by various players in the veterinary vaccines market?

• Which strategies are being applied by market players to sustain in competition in the veterinary vaccines market?

Research Methodology

The process of market research followed at FMI commences with extensive secondary research of the veterinary vaccines market. Analysts obtain industry-validated, historic and current data about the demand for veterinary vaccines across the globe. Comprehensive secondary research is followed by extensive and in-depth primary research, where detailed information about the veterinary vaccines market is obtained in terms of value (US$ million). Based on thorough secondary and primary research about the growth parameters of the veterinary vaccines market, analysts have come up with the most precise forecast about how the veterinary vaccines market will grow during the forecast period.

Note: Request methodology.